Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Naxitamab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Y-mAbs Presents Neuroblastoma Research At AACR Pediatric Cancer Conference
    Y-mAbs Presents Neuroblastoma Research At AACR Pediatric Cancer Conference

    06 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/06/2942097/0/en/Y-mAbs-Presents-Neuroblastoma-Research-on-Naxitamab-and-SADA-PRIT-Technology-Platform-at-AACR-Special-Conference-on-Advances-in-Pediatric-Cancer-Research.html

    GLOBENEWSWIRE
    06 Sep 2024
    Share Share
    Y-mAbs to Participate in Upcoming Investor Conferences in September
    Y-mAbs to Participate in Upcoming Investor Conferences in September

    03 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/03/2939712/0/en/Y-mAbs-to-Participate-in-Upcoming-Investor-Conferences-in-September.html

    GLOBENEWSWIRE
    03 Sep 2024
    Share Share
    Y-mAbs' Naxitamab Shows New Phase 2 Interim Analysis At ASCO 2024
    Y-mAbs' Naxitamab Shows New Phase 2 Interim Analysis At ASCO 2024

    01 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/01/2891814/0/en/Y-mAbs-Announces-New-Interim-Analysis-of-Phase-2-Data-for-Naxitamab-at-2024-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    01 Jun 2024
    Share Share
    Y-mAbs Q1 2024 Results and Recent Developments
    Y-mAbs Q1 2024 Results and Recent Developments

    07 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/07/2877228/0/en/Y-mAbs-Reports-First-Quarter-2024-Financial-Results-and-Recent-Corporate-Developments.html

    GLOBENEWSWIRE
    07 May 2024
    Share Share
    Y-mAbs Therapeutics Naxitamab-gqgk Receives Suppl Approval in the U.S
    Y-mAbs Therapeutics Naxitamab-gqgk Receives Suppl Approval in the U.S

    20 Mar 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761171

    FDA
    20 Mar 2024
    Share Share
    Y-mAbs DANYELZA for the Treatment of High-Risk Neuroblastoma approved in Brazil
    Y-mAbs DANYELZA for the Treatment of High-Risk Neuroblastoma approved in Brazil

    23 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/23/2674387/0/en/Y-mAbs-DANYELZA-naxitamab-gqgk-for-the-Treatment-of-High-Risk-Neuroblastoma-approved-in-Brazil.html

    GLOBENEWSWIRE
    23 May 2023
    Share Share